August 26, 2020 - August 27, 2020
Meeting Materials
The fifty-first meeting of the Advisory Committee on Blood and Tissue Safety and Availability was held on August 26 and 27.
View the Meeting Recording
View a recording of the meeting.
Agenda
August 26, 2020
| TIME | AGENDA ITEM | SPEAKER |
|---|---|---|
|
Committee Business |
||
| 12:30 p.m. | Welcome and Swearing-in |
Admiral Brett P. Giroir, Assistant Secretary for Health Jackie Frederick, MT (ASCP) SBB, MBA, Hon DB/DPH, Chair |
| 12:40 p.m. | Roll Call | James Berger, MS, MT (ASCP) SBB |
| 12:45 p.m. | Purpose of the Meeting |
Jackie Frederick, MT (ASCP) SBB, MBA, Hon DB/DPH, Chair Jay Menitove, MD |
| 1:00 p.m. | Introductory Presentation and Overview of the Public Health Emergencies; Clinical Perspective and Historical Perspective |
Merlyn Sayers, MD, Blood Center and Clinical Perspective Roger Dodd, PhD |
|
Current Experience during the COVID-19 Pandemic |
||
| 1:30 p.m. | AABB Interorganizational Disaster Task Force Response | Brian Gannon, Chairman, AABB Interorganizational Disaster Task Force and CEO, Gulf Coast Regional Blood Center |
| 1:50 p.m. | Experience of Hospitals and Transfusion Services |
Claudia Cohn, MD, CMO, AABB and Associate Professor of Laboratory Medicine and Pathology, University of Minnesota |
| 2:20 p.m. | Experience of Blood Centers: Donor Engagement, Blood Donors and Donation Process, and Public Awareness and Communications | Mike Parejko, CEO, Mississippi Valley Regional Blood Center and President, America's Blood Centers |
| 2:50 p.m. | Afternoon Break | |
| 3:15 p.m. | Experience of Blood Centers: Blood Inventories, Supply Chain, CCP, and Financial Impact |
Bill Block, CEO, Blood Centers of America Chris Hrouda, President, Biomedical Services, American Red Cross David Green, President and CEO, Vitalant |
| 4:15 p.m. | Experience of FDA: Blood Products Industry | Peter Marks, MD, PhD, Director, Center for Biologics Evaluation and Research, FDA |
| 4:45 p.m. | Manufacturer Experience | Dean Gregory, President, Global Commercial Operations for Transfusion Medicine and Cell Therapy, Fresenius Kabi |
| 5:15 p.m. | Adjournment | |
August 27, 2020
| TIME | AGENDA ITEM | SPEAKER |
|---|---|---|
|
Committee Business |
||
| 8:30 a.m. | Call to Order | Jackie Fredrick, MT (ASCP) SBB, MBA, Hon DB/DPH |
| 8:40 a.m. | Roll Call | James Berger, MS, MT (ASCP) SBB |
| 8:50 a.m. | First Day Recap of the Meeting | Jay Menitove, MD |
| 9:00 a.m. | Government Data Collection Systems for Transfusion Medicine and Blood Operations |
Steven A. Anderson, PhD, MPP, Director, Office of Biostatistics and Epidemiology, Center for Biologics Evaluation and Research, FDA Sridhar V. Basavaraju, MD, Director, Office of Blood, Organ, and Other Tissue Safety, Centers for Disease Control and Prevention Simone Glynn MD, MSc, MPH, Chief, Blood Epidemiology and Clinical Therapeutics Branch, National Heart, Lung, and Blood Institute |
|
Stakeholder Statements and Presentations |
||
| 9:30 a.m. | Patient Perspective | Nathan Schafer, APLUS |
| 9:50 a.m. | AABB | Debra BenAvram, FASAE, CAE, CEO, AABB |
| 10:10 a.m. | America's Blood Centers | Kate FryMBA, CAE, CEO, America's Blood Centers
|
| 10:30 a.m. | American Red Cross | Chris Hrouda, President, Biomedical Services, American Red Cross |
| 10:50 a.m. | Morning Break | |
| 11:05 a.m. | U.S. Department of Defense | Colonel Audra L. Taylor, Division Chief, Armed Services Blood Program, U.S. Department of Defense |
| 11:25 a.m. | Plasma Protein Therapeutics Association | Amy Efantis, President and CEO, Plasma Protein Therapeutics Association |
| 11:45 a.m. | Public Comment | |
| 12:00 p.m. | Lunch | |
|
Considerations for the Future |
||
| 1:00 p.m. | Blood-based Therapies for Patient Treatment, CCP, and Other Immunotherapies | Michael Joyner, MD, Mayo Clinic |
| 1:30 p.m. | Innovation in Blood Products for the Future, Responding to Public Health Emergencies | John Holcomb, MD |
| 2:00 p.m. | Q&A |
Michael Joyner, MD, Mayo Clinic John Holcomb, MD |
| 2:30 p.m. | Afternoon Break | |
|
Discussion, Questions, and Recommendations |
||
| 2:45 p.m. | Committee Discussion | |
| 3:45 p.m. | Formulation of Committee Findings and Recommendations | Jay Menitove, MD |
| 4:45 p.m. | New Business and Next Steps | Jackie Frederick, MT (ASCP) SBB, MBA, Hon DB/DPH, Chair |
| 5:00 p.m. | Adjournment | James Berger, MS, MT (ASCP) SBB |
